Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015
ReportsWeb.com has announced the addition of the “Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015” this report provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeut
(EMAILWIRE.COM, June 24, 2017 ) This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/chronic-coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001172195/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
Human Stem Cells Institute
Juventas Therapeutics, Inc.
Lacer, S.A.
Nuo Therapeutics, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001172195/discount
List of Tables
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Human Stem Cells Institute, H1 2015 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Juventas Therapeutics, Inc., H1 2015 14
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lacer, S.A., H1 2015 15
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Nuo Therapeutics, Inc., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics-Recent Pipeline Updates, H1 2015 34
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects, H1 2015 37
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001172195/buy/2000
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/chronic-coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001172195/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
Human Stem Cells Institute
Juventas Therapeutics, Inc.
Lacer, S.A.
Nuo Therapeutics, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001172195/discount
List of Tables
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Human Stem Cells Institute, H1 2015 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Juventas Therapeutics, Inc., H1 2015 14
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lacer, S.A., H1 2015 15
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Nuo Therapeutics, Inc., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics-Recent Pipeline Updates, H1 2015 34
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects, H1 2015 37
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001172195/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results